Use of anticoagulants increases risk of bleeding after colorectal endoscopic submucosal dissection

Abstract

Background and study aims Japanese guidelines for gastroenterological endoscopy have recommended temporary withdrawal of anticoagulants (warfarin, direct oral anticoagulants [DOAC], or heparin) to prevent hemorrhagic complications during endoscopic submucosal dissection (ESD) for colorectal neoplasias (CRNs). However, serious thrombosis might occur during temporary withdrawal of anticoagulants. The current study aimed to evaluate outcomes with anticoagulants in patients undergoing ESD for CRNs.

Patients and methods This study was a single-institution retrospective cohort study based on clinical records. We assessed 650 consecutive patients with 698 CRNs who underwent ESD at Hiroshima University Hospital between December 2010 and June 2016. The patients were divided into three groups: the warfarin group (19 patients with 19 CRNs), DOAC group (7 patients with 9 CRNs), and no-antithrombotics group (624 patients with 670 CRNs). We replaced warfarin with heparin 3 to 5 days before endoscopy. Although DOAC was suspended on the morning of endoscopy, we did not replace heparin.

Results Bleeding after the procedure occurred in 26.3 % (5/19), 22.0 % (2/9), and 2.7 % (18/670) of patients in the warfarin, DOAC, and no-antithrombotics groups, respectively. In the warfarin group, four patients who bled after the procedure took not only warfarin but also other antiplatelets. En bloc resection rates were 94.7 % (18/19), 100 % (9/9), and 96.6 % (647/670) in the warfarin, DOAC, and no-antithrombotics groups, respectively. No patients experienced ischemic events in the perioperative period.

Conclusions Among patients undergoing ESD for CRNs, risk of bleeding was higher among patients who took anticoagulants than among those who did not. In particular, careful attention to patients who took antiplatelets in addition to warfarin before ESD for CRNs is warranted.

• References

• 1 Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610-1616
• 2 Garcia DA, Regan S, Henault LE. et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-69
• 3 Anderson MA, Ben-Menachem T, Gan SI. et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060-1070
• 4 Boustière C, Veitch A, Vanbiervliet G. et al. European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2011; 43: 445-461
• 5 Veitch AM, Baglin TP, Gershlick AH. et al. Guidelines for the management of anticoagulants and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008; 57: 1322-1329
• 6 Fujimoto K, Fujishiro M, Kato M. et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014; 26: 1-14
• 7 Oka S, Tanaka S, Kaneko I. et al. Advantage of endoscopic submucosal dissection compared with EMR for early gastric cancer. Gastrointest Endosc 2006; 64: 877-883
• 8 Shigita K, Oka S, Tanaka S. et al. Long-term outcomes after endoscopic submucosal dissection for superficial colorectal tumors. Gastrointest Endosc 2017; 85: 546-553
• 9 Boda K, Oka S, Tanaka S. et al. Clinical outcome of endoscopic submucosal dissection for colorectal tumors. Gastrointest Endosc 2018; 87: 714-722
• 10 Oka S, Tanaka S, Saito Y. et al. Local recurrence after endoscopic resection for large colorectal neoplasia: A multicenter prospective study in Japan. Am J Gastroenterol 2015; 110: 697-707
• 11 Takeuchi Y, Iishi H, Tanaka S. et al. Factors associated with technical difficulties and adverse events of colorectal endoscopic submucosal dissection: Retrospective exploratory factor analysis of a multicenter prospective cohort. Int J Colorectal Dis 2014; 29: 1275-1284
• 12 Oka S, Tanaka S, Kanao H. et al. Current status in the occurrence of postoperative bleeding, perforation and residual/local recurrence during colonoscopic treatment in Japan. Dig Endosc 2010; 22: 376-380
• 13 Sanomura Y, Oka S, Tanaka S. et al. Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer. Gastric Cancer 2014; 17: 489-496
• 14 Higashiyama M, Oka S, Tanaka S. et al. Risk factors for bleeding after endoscopic submucosal dissection of gastric epithelial neoplasm. Dig Endosc 2011; 23: 290-295
• 15 Ninomiya Y, Oka S, Tanaka S. et al. Risk of bleeding after endoscopic submucosal dissection for colorectal tumors in patients with continued use of low-dose aspirin. J Gastroenterol 2015; 50: 1041-1046
• 16 Tajiri H, Kitano S. Complications associated with endoscopic mucosal resection: Definition of bleeding that can be viewed as accidental. Dig Endosc 2004; 16: 134-136
• 17 Fujita M, Shiotani A, Murao T. et al. Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics. Dig Endosc 2015; 27: 25-29
• 18 Inoue T, Nishida T, Maekawa A. et al. Clinical features of post-polypectomy bleeding associated with heparin bridge therapy. Dig Endosc 2014; 26: 243-249
• 19 Matsumoto M, Mabe K, Tsuda M. et al. Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis. BMC Gastroenterol 2015; 15: 89-96
• 20 Hui AJ, Wong RM, Ching JY. et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: Analysis of 1657 cases. Gastrointest Endosc 2004; 59: 44-48
• 21 Suzuki S, Chino A, Kishihara T. et al. Risk factors for bleeding after endoscopic submucosal dissection of colorectal neoplasms. World J Gastroenterol 2014; 20: 1839-1845
• 22 Takeuchi T, Ota K, Harada S. et al. The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. BMC Gastroenterol 2013; 13: 136-143
• 23 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955-962
• 24 Ono S, Fujishiro M, Niimi K. et al. Technical feasibility of endoscopic submucosal dissection for early gastric cancer in patients taking anti-coagulants or anti-platelet agents. Digest Liver Dis 2009; 41: 725-728
• 25 Matsumura T, Arai M, Maruoka D. et al. Risk factors for early and delayed post-operative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agents. BMC Gastroenterol 2014; 14: 172-180
• 26 Shindo Y, Matsumoto S, Miyatani H. et al. Risk factors for postoperative bleeding after gastric endoscopic submucosal dissection in patients under antithrombotics. World J Gastrointest Endosc 2016; 8: 349-356
• 27 Terasaki M, Tanaka S, Shigita K. et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for colorectal neoplasms. Int J Colorectal Dis 2014; 29: 877-882
• 28 Fujii T, Ono A, Fu KI. A novel endoscopic suturing technique using a specially designed so-called “8-ring” in combination with resolution clips (with video). Gastrointest Endosc 2007; 66: 1215-1220
• 29 Otake Y, Saito Y, Sakamoto T. et al. New closure technique for large mucosal defects after endoscopic submucosal dissection of colorectal tumors (with video). Gastrointest Endosc 2012; 75: 663-667
• 30 Matsuda T, Fujii T, Emura F. et al. Complete closure of a large defect after EMR of a lateral spreading colorectal tumor when using a two-channel colonoscope. Gastrointest Endosc 2004; 60: 836-838
• 31 Pollack CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-520